Rucaparib or Rubraca, the advanced ovarian cancer treatment, has received an accelerated approval from the FDA.
The announcement came earlier this week. On December 19, the FDA announced that it has granted and accelerated rucaparib approval.
However, the FDA or the United States Food and Drug Administration imposed a limitation. The accelerated approval will target BRCA genes cases.
BRCA or “deleterious BRCA” are specific gene mutations. BRCA 1 and 2 genes are generally beneficial. They help in the damaged DNA repair process. When this option is unavailable, they help destroy the affected cells.
If BRCA genes suffer mutations, they could come to increased breast cancer risks. The causes of these mutations are varied. Some have been proven harmful, others seem to have no impact.
The percent of breast cancer cases to present such a mutation are rare. However, its effects are more profound. Women with BRCA 1 or 2 mutations might have a five times higher risk of developing breast cancer.
BRCA genes are also naturally designed to prevent tumor growth. Following their announcement, the FDA also released a series of details.
Rubraca, for example, targets damaged BRCA genes. It was specifically designed to do so. It helps a specific enzyme that is usually produced by such a gene.
The FDA announcement also targeted the FoundationFocus CDxBRCA test. This is a new diagnostic test. It is a first-generation sequencing test to be approved by the administration.
FoundationFocus CDxBRCA screenings will test for ovarian cancer mutations. It is capable of detecting both BRCA 1 and 2 alterations.
Rucaparib treatments will also only target recurring cancer cases. The PARP inhibitor will be approved for ovarian cancer cases with deleterious BRCA mutations.
The approval targets patients that have already gone through at least two treatment regimens. Chemotherapy regimens are included in the treatments.
Rubraca’s accelerated approval was also based on trials. Rucaparib had already been granted a Priority Review status. The trials were single-armed, multicenter, and open-labeled.
They included 106 patients suffering from advanced ovarian cancer. All involved sufferers had been treated with at least two prior therapies. These either had no effect, or the cancer reoccurred.
FoundationFocus CDxBRCA tests were also carried out. They confirmed the mutations in 96 percent of the cases to have available samples. Its verification was made in retrospect but was still useful.
Trial objective response rates or ORR revealed encouraging results. ORR for rucaparib treated patients reached 54 percent.
The average response duration reached 9.2 months. Rucaparib was proven to have benefited 57 of the involved patients.
Platinum-resistant, sensitive, or refractory patient responses were also tested. As such, platinum-sensitive patients had a 66 percent ORR. Platinum-refractory sufferers, in contrast, had a 0 percent ORR. Platinum-resistant patients had an ORR reaching 25 percent.
Mutation-specific rates were also analyzed. However, BRCA 1 or 2 gene mutations showed no difference in the rucaparib ORR.
Drug adverse reactions were also tested. Such a safety cohort included a number of 377 patients. They all showed the most common side-effects.
These included fatigue, nausea, anemia, vomiting, appetite loss, abdominal pains, and unusual taste sensations.
Such reactions led to a discontinued drug use in 10 percent of the patients. Among such patients, the most common effects were asthenia/fatigue.
The FDA granted the accelerated approval, still, it also pointed out some requirements. It noted that patients using rucaparib should be monitored.
Their hematological toxicity should be registered at the baseline and on a monthly basis. Such a practice should be carried out over the whole treatment duration.
Most consider the accelerated approval a good decision. Rucaparib is considered to be a potentially important advance in treating advanced cancer cases suffering from BRCA mutations.
Image Source: Wikimedia